Henrotin Yves E, Michlmayr Christoph, Rau Stefanie M, Quirke Anne-Marie, Bigoni Marco, Ueberall Michael A
musculoSKeletal Innovative Research Lab (mSKIL), Institute of Pathology, Level 5, Center for Interdisciplinary Research on Medicines (CIRM), Department of Motricity Sciences, Centre Hospitalier Universitaire Sart-Tilman, University of Liège, Liège, Belgium.
Department of Physical Therapy and Rehabilitation, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Belgium.
Rheumatol Ther. 2022 Oct;9(5):1305-1327. doi: 10.1007/s40744-022-00472-7. Epub 2022 Jul 26.
Osteoarthritis is the most common joint disorder affecting over 300 million people worldwide. It typically affects the knees and the hips, and is characterized by a loss in normal joint movement, stiffness, swelling, and pain in patients. The current gold standard therapy for osteoarthritis targets pain management using nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are associated with several potentially serious side effects, the most common being gastrointestinal perforation and bleeding. Owing to the side effects, NSAID treatment doses need to be as low as possible and should be continued for the shortest duration possible, which is problematic in a chronic condition like osteoarthritis, which requires long-term management. Numerous clinical trials have examined oral enzyme combinations as a potential new approach in managing pain in patients with osteoarthritis. Oral enzyme combinations containing bromelain in combination with trypsin, both proteolytic enzymes, as well as the plant flavonoid rutin, may be an effective alternative to typical NSAIDs. The aim of this narrative review is to summarize and discuss the evidence on the efficacy of oral enzyme combinations compared to the gold standard (NSAID) in the management of osteoarthritis symptoms. Nine randomized controlled trials identified in this review assessed the efficacy and safety of the oral enzyme combination containing bromelain, trypsin, and rutin in patients with osteoarthritis. Most of the studies assessed the impact of the oral enzyme combination on the improvement of the Lequesne Algofunctional index score, treatment-related pain intensity alterations and adverse events compared to patients receiving NSAIDs. Although largely small scale, the study outcomes suggest that this combination is as effective as NSAIDs in the management of osteoarthritis, without the adverse events associated with NSAID use. INFOGRAPHIC.
骨关节炎是最常见的关节疾病,全球有超过3亿人受其影响。它通常影响膝盖和臀部,患者的特征是正常关节活动丧失、僵硬、肿胀和疼痛。目前骨关节炎的金标准治疗方法是使用非甾体抗炎药(NSAIDs)来控制疼痛。NSAIDs与几种潜在的严重副作用相关,最常见的是胃肠道穿孔和出血。由于这些副作用,NSAIDs治疗剂量需要尽可能低,且应持续尽可能短的时间,这在像骨关节炎这种需要长期管理的慢性病中是个问题。许多临床试验已经研究了口服酶组合作为管理骨关节炎患者疼痛的一种潜在新方法。含有菠萝蛋白酶与胰蛋白酶(均为蛋白水解酶)以及植物类黄酮芦丁的口服酶组合,可能是典型NSAIDs的有效替代品。本叙述性综述的目的是总结和讨论与金标准(NSAID)相比,口服酶组合在管理骨关节炎症状方面疗效的证据。本综述中确定的9项随机对照试验评估了含有菠萝蛋白酶、胰蛋白酶和芦丁的口服酶组合对骨关节炎患者的疗效和安全性。大多数研究评估了与接受NSAIDs的患者相比,口服酶组合对改善Lequesne功能指数评分、治疗相关疼痛强度变化和不良事件的影响。尽管规模大多较小,但研究结果表明,这种组合在管理骨关节炎方面与NSAIDs一样有效,且没有与使用NSAIDs相关的不良事件。信息图。